We post reviews for MSK healthcare providers who have at least 30 patient experience surveys completed. If you do not see reviews for a provider, it may be because they do not yet have enough survey responses, or the provider may not be part of the group of healthcare providers included in the survey.
Only outpatient providers are included in the survey. Healthcare providers who only work in the hospital or in urgent care are not included in the survey. Pathologists or researchers who do not provide direct care to patients do not have reviews.
I am an attending research clinical chemist in the Departments of Laboratory Medicine, Surgery (Urology Service), and Medicine (Genitourinary Oncology Service) at Memorial Sloan Kettering Cancer Center. With my discovery of free PSA and other prostate-related proteins, I am primarily interested in circulating tumor markers that predict the development and progression of prostate cancer, as well as the possibility that these related markers play a key role in the pathogenesis of prostate cancer. I have contributed to over 180 peer-reviewed scientific publications, primarily detailing the relationship of biomarker proteins, prostate physiology, and pathology. I was a tenured professor at Lund University in Sweden until I moved to Memorial Sloan Kettering Cancer Center, and I still maintain an active relationship with my former laboratory at Lund University.
Read more
My Role at MSK
A clinical chemist is a scientist with special training in looking for signs of disease in bodily fluids, such as blood.
Areas of Expertise
My Specialties
Prostate cancer
Education & Honors
Education
MD, PhD, Lund University (Sweden)
Residencies
Lund University Hospital (Sweden)
Insurance Information
Understanding your insurance options is an important part of managing your cancer care. We have relationships with many common healthcare providers and plans.
Aetna
In Network Coverage Type HMO, EPO PPO, POS, Transplant
Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.
Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.
You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.
Visit PubMed for a full listing of Dr. Lilja’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.
We strive to keep reviews trustworthy, honest and fair.
Learn more about our patient experience reviews.
Disclosures
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Hans G. Lilja discloses the following relationships and financial interests:
AcouSort Equity
Arctic Partners Equity; Intellectual Property Rights
Diaprost AB Equity; Intellectual Property Rights
Fujirebio Diagnostics, Inc. Professional Services and Activities
OPKO Health, Inc. Equity; Intellectual Property Rights
If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.
The information published here is a complement to other publicly reported data and is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2023 through disclosure submission in spring 2024). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].
